Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospitals Cleveland Medical Center
With
Sanofi
The study will consist of a 30 day screening/washout phase at the end of which qualified subjects will be assigned to alfuzosin 10 mg tablets once a day. Subjects will be treated for 90 days. The total duration of the study will be 120 days.
Age
45–75
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Males 45-75 years of age
Confirmed diagnosis of BPH/lower urinary tract symptoms (LUTS) and ED
Men with steady partner and who agree to attempt sex once a week.
You may not be if
Prostate cancer
Prostatitis
Penile disease
Cardiac co-morbidity
Pre-existing co-morbid conditions
History of sensitivity to the drug or similar drugs
Enrollment in another clinical trial
Impaired hepatic function
Impaired renal function
Mental conditions rendering subject unable to understand the study
